---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-008777"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T08:48:05.094914+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NRx Pharma posts FY2024 operating loss of $18.5M; NDA filings for ketamine and bipolar drug anticipated in 2025

## Summary
- Q4 2024 operating loss $2.4M, down 45% YoY; FY2024 operating loss $18.5M vs $27.8M in 2023.
- Received non-binding terms for NRX-100 license with >$300M milestones plus double-digit royalties.
- Initiated NDA for NRX-100 (IV ketamine) and plans NDA for NRX-101 (bipolar depression); both target PDUFA dates before Dec 31, 2025.
- HOPE Therapeutics signed LOIs to acquire three precision psychiatry centers; negotiating for six more; BTIG engaged as advisor.
- Cash $1.4M at Dec 31, 2024; raised $8.5M in Jan 2025; management expects sufficient cash through end of 2025.

## SEC filing metadata
- accession: 0001437749-25-008777
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/0001437749-25-008777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925008777/nrxp20250319_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-008777
- JSON: https://secwatch.observer/filing/0001437749-25-008777.json
- Plain text: https://secwatch.observer/filing/0001437749-25-008777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.